妊娠期接种呼吸道合胞病毒预融合F蛋白疫苗后的母婴结局:2024-2025年法国免疫接种活动分析
基于法国覆盖近99%人口的国家健康数据库,纳入2024年9月16日至12月31日妊娠22周后分娩的全部女性,将接种RSVpreF疫苗者与未接种者按1:1匹配。匹配队列中未观察到早产、死产、剖宫产、小于胎龄儿、产后出血、子痫前期或主要不良心血管事件风险显著增加。
要点
- 匹配后接种组与未接种组各24891例,早产加权IRR 0.97(95%CI 0.89-1.06)。
- 接种后1周内分娩加权IRR 0.81(95%CI 0.72-0.90),3周内分娩加权IRR 0.97(95%CI 0.93-1.00)。
- 妊娠32周及以前接种者早产风险未见显著增加,加权IRR 1.13(95%CI 0.98-1.31)。
核心结论
- 这项大型观察性研究发现,妊娠期接种RSVpreF疫苗未观察到重大安全性问题。
- 作者指出需进一步研究,包括国际比较及相对于抗RSV单克隆抗体的有效性评估,以充分描述RSVpreF的获益-风险平衡。
- 作者强调持续监测仍至关重要,尤其需监测罕见不良事件。
研究设计与样本
- 基于法国国家健康数据库的观察性研究,该数据库覆盖法国近99%的人口。
- 纳入2024年9月16日至12月31日妊娠22周后分娩的全部女性。
- 接种RSVpreF疫苗的女性与未接种女性按1:1匹配,匹配因素包括接种时孕周、妊娠开始时母亲年龄、居住地区、受孕周、早产史、同次妊娠流感疫苗接种及多胎妊娠。
- 研究期间共有29032名女性接种疫苗,其中24891名(85.7%)成功匹配至24891名未接种对照。
- 匹配队列中母亲平均年龄30.9±5.0岁,3.2%有早产史,0.6%为多胎妊娠,21.8%接种过流感疫苗。
主要发现
- 早产加权IRR 0.97(95%CI 0.89-1.06)。
- 接种后1周内分娩加权IRR 0.81(95%CI 0.72-0.90),3周内分娩加权IRR 0.97(95%CI 0.93-1.00)。
- 死产加权IRR 0.77(95%CI 0.45-1.32),剖宫产加权IRR 1.00(95%CI 0.96-1.03)。
- 小于胎龄儿出生体重加权IRR 1.01(95%CI 0.96-1.07),产后出血加权IRR 1.03(95%CI 0.97-1.10)。
- 子痫前期加权IRR 1.02(95%CI 0.85-1.22),主要不良心血管事件加权IRR 0.60(95%CI 0.26-1.40)。
局限性
- 作者指出需进一步研究,包括国际比较及相对于抗RSV单克隆抗体的有效性评估,以充分描述RSVpreF的获益-风险平衡。
- 作者强调持续监测仍至关重要,尤其需监测罕见不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety of the respiratory syncytial virus prefusion F protein (RSVpreF) vaccine in pregnant women during the 2024-2025 French immunization campaign, with a particular focus on the risk of preterm birth. METHODS: Using the national health care database, which covers almost 99% of the population in France, we included all women who gave birth after 22 weeks of gestation between September 16 and December 31, 2024. Women vaccinated with RSVpreF were matched 1:1 with unvaccinated women on the basis of gestational age at vaccination, maternal age at pregnancy onset, region of residence, week of conception, history of preterm birth, influenza vaccination during the same pregnancy, and multiple pregnancy. Outcomes included preterm birth, delivery within 1 and 3 weeks after vaccination, stillbirth, small-for-gestational-age (SGA) birth weight, cesarean delivery, hemorrhage, preeclampsia, and major cardiovascular events, including maternal death. Time-to-event analyses were conducted with Poisson regression models with robust variance to estimate weighted incidence rate ratios (IRRs) and their 95% CIs for each outcome. RESULTS: Among the 29,032 women vaccinated during the study period, 24,891 (85.7%) were successfully matched to 24,891 unvaccinated women in a control group. In the matched cohort, the mean±SD maternal age was 30.9±5.0 years, 3.2% had a history of preterm birth, 0.6% had multiple pregnancies, and 21.8% had received influenza vaccination. No significant increase in the risk of the following outcomes was observed: preterm birth (weighted IRR 0.97, 95% CI, 0.89-1.06), delivery within 1 week (weighted IRR 0.81, 95% CI, 0.72-0.90) or within 3 weeks (weighted IRR 0.97, 95% CI, 0.93-1.00), stillbirth (weighted IRR 0.77, 95% CI, 0.45-1.32), cesarean delivery (weighted IRR 1.00, 95% CI, 0.96-1.03), SGA birth weight (weighted IRR 1.01, 95% CI, 0.96-1.07), postpartum hemorrhage (weighted IRR 1.03, 95% CI, 0.97-1.10), preeclampsia (weighted IRR 1.02, 95% CI, 0.85-1.22), or major adverse cardiovascular event (weighted IRR 0.60, 95% CI, 0.26-1.40) outcomes. Among women vaccinated at or before 32 weeks of gestation, no significant increase in the risk of preterm birth was observed (weighted IRR 1.13, 95% CI, 0.98-1.31). CONCLUSION: This large observational study found no major safety concerns associated with RSVpreF vaccination during pregnancy. Further research, including international comparisons and evaluations of effectiveness relative to monoclonal antibodies against RSV, will be needed to fully characterize the benefit-risk balance of RSVpreF. Ongoing surveillance remains essential, particularly to monitor rare adverse events.
引用
- Gabet A, Bertrand M, Jabagi MJ, et al. Maternal and Neonatal Outcomes After Respiratory Syncytial Virus Prefusion F Protein Vaccination During Pregnancy: Analysis From the 2024-2025 Immunization Campaign in France. Obstet Gynecol. 2025. PMID: 41232114. doi:10.1097/AOG.0000000000006121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。